Early InvestigationalResearch Use Only

5-Amino-1MQ

Small molecule nicotinamide N-methyltransferase (NNMT) inhibitor. Reduces SAM consumption, supports NAD+ precursor availability, and modulates adipocyte metabolism. Early-stage investigational compound with preclinical metabolic data.

MetabolicNNMT InhibitorNAD+ PathwayAdipocyte ResearchOralSmall Molecule

QUICK FACTS

FULL NAME5-Amino-1-methylquinolinium

CLASSNNMT inhibitor — small molecule

TARGETNNMT enzyme in adipose tissue

NAD+ LINKReduces SAM competition → supports NAD+ pathway

ROUTEOral — small molecule bioavailability

Overview

5-Amino-1MQ (5-amino-1-methylquinolinium) is a small molecule inhibitor of nicotinamide N-methyltransferase (NNMT), an enzyme highly expressed in adipose tissue. NNMT methylates nicotinamide using S-adenosylmethionine (SAM) as the methyl donor, and elevated NNMT activity in obesity is associated with reduced NAD+ precursor availability and impaired adipocyte metabolism. By inhibiting NNMT, 5-Amino-1MQ reduces SAM consumption and increases nicotinamide availability for NAD+ synthesis. Preclinical research has shown reduced adipocyte differentiation, increased fat cell metabolism, and improved metabolic parameters. Oral bioavailability is an advantage over most peptides. Early-stage investigational compound — limited human clinical data currently available.

Research Areas

NNMT enzyme pharmacologyAdipose tissue metabolism researchNAD+ pathway modulationObesity researchMetabolic syndrome researchSmall molecule metabolic research

Available Evidence

PreclinicalRodent studies demonstrate NNMT inhibition, reduced adipocyte differentiation, and metabolic improvements. Mechanism well-characterized.

MechanisticSAM/NAD+ pathway interaction pharmacologically established in cell and animal models.

Human Data (limited)Early-stage investigational. Limited human clinical data available.

Documented Research Benefits

NNMT inhibition

preclinical

Fat cell metabolism

preclinical

NAD+ pathway support

mechanistic

Oral bioavailability

pharmacological

SAM pathway modulation

mechanistic

Adipocyte research

preclinical

What are you researching?

Tell us your focus area and we’ll send a personalized research guide.

Safety & Regulatory Status

Early-stage investigational. Limited human safety data. Preclinical safety established in rodent models. Not for use in persons with NAD+ pathway disorders without guidance. All information educational reference only.